Cannabis Science Inc. (OTC: CBIS), a medical marijuana company at the forefront of pharmaceutical grade medical marijuana research and development, this week, provided investors with an update on its product line advancements.
CBIS said that some of its products are currently available to patents with legal state medical marijuana access. The other products are up and coming OTC products that will be made available in the U.S. and internationally, the company said.
At the moment, Cannabis Science is working towards making critical cannabis-based medications more widely available. In order to achieve this goal, the Colorado-based company has initiated, with the help of its FDA advisory group, a pre-IND process.
Cannabis Science is also very excited about its OTC skin and nutraceutical product lines that are currently in development. The development of this product line is being headed by Dr. Moe Afaneh, who is CBIS’ COO.
CBIS plans to work with specifically appointed legal providers and laboratories to expand the availability of its formulations across the U.S. and the world where legally available.
As CBIS continues to make steady progress, the company’s shares have remained in focus since the start of this year. In fact, CBIS has been one of best performing penny stocks this year, gaining more than 985% since the start of this year.
Recent Comments